Literature DB >> 22057134

Ibandronate for prevention and treatment of glucocorticoid-induced osteoporosis in rabbits.

Kun-Juan Zhang1, Jian Zhang, Ze-Kun Kang, Xiao-Mei Xue, Jing-Fen Kang, Yan-Wei Li, Hai-Ning Dong, Dong-Gang Liu.   

Abstract

The objective of this study is to evaluate the efficacy of ibandronate (IBN) in prevention and treatment of glucocorticoid-induced osteoporosis in rabbits. A total of 60 New Zealand white rabbits were randomly allocated into six groups. Twenty rabbits in the control group were injected with saline. Forty rabbits received dexamethasone (DX) treatment at a dose of 3 mg/kg twice weekly during the first 6 weeks, while 10 of these rabbits (group IBN&amp;DX) were injected additionally with IBN at a dose of 2 mg/kg before DX treatment. At week 6, the rabbits from IBN&amp;DX group, 10 rabbits from control group (group CNTR-1) and 10 rabbits treated with DX (group DX6) were killed. Half (10) of the remaining rabbits in DX group were continued for DX treatment at a dose of 3 mg/kg once weekly (group DX12), while the other half (10) rabbits (group DX&amp;IBN) additionally received IBN injection (2 mg/kg) once before continuing DX treatment. The remaining rabbits (10) in an additional of control group (group CNTR-2) continuously received saline. At week 12, all rabbits were killed for bone biomechanical analysis and histological examination. At week 6, the analysis of bone biomechanical and histological results of group CNTR-1 and DX6 showed that GIOP rabbit models were successfully established. Compared with group DX6, bone volume/tissue volume (BV/TV), trabecular number (Tb.N) and trabecular thickness (Tb.Th) of lumbar spine in group IBN&amp;DX were increased by 100, 45.74 and 40.55%, respectively (P < 0.01). Meanwhile, BV/TV and Tb.N of femoral neck were increased by 30.29 and 16.86%, respectively (P < 0.01). The maximum compressive load, the maximum bending stress and the maximum torque were increased by 24.19, 29.91 and 37.24%, respectively (P < 0.01). At week 12, in comparison of the results between group DX12 and group DX6, the histomorphometric and mechanical analysis demonstrated that prolonged DX treatment could lead to further loss of bone mass and strength. Compared with group DX12, BV/TV, Tb.N and Tb.Th of lumbar spine in group DX&amp;IBN were increased by 73.34, 39.02 and 23.87%, respectively (P < 0.05), the parameters of femoral neck were increased by 88.75, 31.29 and 42.01%, respectively (P < 0.01), and the biomechanical parameters were increased by 54.36, 21.38 and 105.75%, respectively (P < 0.05). IBN could effectively prevent and treat high-dosing glucocorticoid-induced loss of bone mass and strength in rabbits.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22057134     DOI: 10.1007/s00296-011-2074-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  34 in total

1.  Ibandronate treatment reverses glucocorticoid-induced loss of bone mineral density and strength in minipigs.

Authors:  C C Glüer; K E Scholz-Ahrens; A Helfenstein; G Delling; W Timm; Y Açil; R Barkmann; J Hassenpflug; B Stampa; F Bauss; J Schrezenmeir
Journal:  Bone       Date:  2006-12-15       Impact factor: 4.398

Review 2.  Management of glucocorticoid-induced osteoporosis.

Authors:  Juliet Compston
Journal:  Nat Rev Rheumatol       Date:  2010-02       Impact factor: 20.543

Review 3.  Use of oral corticosteroids and risk of fractures.

Authors:  T P Van Staa; H G Leufkens; L Abenhaim; B Zhang; C Cooper
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

Review 4.  Glucocorticoid-induced osteoporosis: an update.

Authors:  Gherardo Mazziotti; Alberto Angeli; John P Bilezikian; Ernesto Canalis; Andrea Giustina
Journal:  Trends Endocrinol Metab       Date:  2006 May-Jun       Impact factor: 12.015

5.  The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France.

Authors:  Joyce A Cramer; Niall O Lynch; Anne-Francoise Gaudin; Mel Walker; Warren Cowell
Journal:  Clin Ther       Date:  2006-10       Impact factor: 3.393

6.  The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression.

Authors:  Shreyasee Amin; Michael P Lavalley; Robert W Simms; David T Felson
Journal:  J Bone Miner Res       Date:  2002-08       Impact factor: 6.741

7.  Skeletal effects of short-term exposure to dexamethasone and response to risedronate treatment studied in vivo in rabbits by magnetic resonance micro-imaging and spectroscopy.

Authors:  Masaya Takahashi; Punam K Saha; Felix W Wehrli
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

8.  Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.

Authors:  J D Ringe; A Dorst; H Faber; K Ibach; F Sorenson
Journal:  Osteoporos Int       Date:  2003-08-28       Impact factor: 4.507

9.  Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.

Authors:  John A Eisman; Roberto Civitelli; Silvano Adami; Edward Czerwinski; Chris Recknor; Richard Prince; Jean-Yves Reginster; Mone Zaidi; Dieter Felsenberg; Claire Hughes; Nicole Mairon; Daiva Masanauskaite; David M Reid; Pierre D Delmas; Robert R Recker
Journal:  J Rheumatol       Date:  2008-02-01       Impact factor: 4.666

10.  Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer.

Authors:  P Heras; K Kritikos; A Hatzopoulos; A-P Georgopoulou
Journal:  Eur J Cancer Care (Engl)       Date:  2009-06-22       Impact factor: 2.520

View more
  2 in total

1.  Glucocorticoids activate the local renin-angiotensin system in bone: possible mechanism for glucocorticoid-induced osteoporosis.

Authors:  Zhang Yongtao; Wang Kunzheng; Zheng Jingjing; Shan Hu; Kou Jianqiang; Liu Ruiyu; Wang Chunsheng
Journal:  Endocrine       Date:  2014-02-12       Impact factor: 3.633

Review 2.  Rabbit as model for osteoporosis research.

Authors:  María Permuy; Mónica López-Peña; Fernando Muñoz; Antonio González-Cantalapiedra
Journal:  J Bone Miner Metab       Date:  2019-05-13       Impact factor: 2.626

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.